Description

[2-[4-[5-[4-acetyloxy-6-methyl-5-(6-methyl-5-oxo-oxan-2-yl)oxy-oxan-2- yl]oxy-4-dimethylamino-6-methyl-oxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxo-ethyl] acetate is a complex, semi-synthetic anthracycline derivative of significant interest in advanced pharmaceutical research. Its intricate molecular structure is engineered to serve as a key intermediate or active pharmaceutical ingredient (API) in the development of novel chemotherapeutic agents. This compound is primarily utilized by pharmaceutical R&D laboratories and manufacturers specializing in oncology drug development and production.

Application

• Pharmaceutical Intermediate: Critical precursor in the synthesis of next-generation anthracycline-based chemotherapeutic drugs.
• Oncology Research: Used as a reference standard or active compound in biochemical and pharmacological studies targeting DNA intercalation and topoisomerase II inhibition.
• API Manufacturing: Serves as a building block for the production of complex anti-cancer Active Pharmaceutical Ingredients (APIs) under Good Manufacturing Practice (GMP) conditions.
• Mechanistic Studies: Employed in academic and industrial research to investigate structure-activity relationships (SAR) and mechanisms of action for anthracycline derivatives.
• Drug Discovery & Development: Integral component in the discovery pipeline for novel anti-tumor agents, particularly for solid tumors and leukemias.

Basic Information

Product Name	[2-[4-[5-[4-acetyloxy-6-methyl-5-(6-methyl-5-oxo-oxan-2-yl)oxy-oxan-2- yl]oxy-4-dimethylamino-6-methyl-oxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxo-ethyl] acetate
CAS No.	81975-88-4
Molecular Formula	C46H55NO19
Molecular Weight	925.93 g/mol
Synonyms	4'-O-Acetyl-4-demethoxydaunorubicin 13-acetate; 4'-O-Acetyl-4-demethoxy-13-dihydrodaunorubicin 13-acetate; Idarubicin related compound F (EP Impurity F); 4-Demethoxydaunorubicin 4',13-diacetate; Idarubicin impurity F; 4'-O-Acetyl-4-demethoxydaunorubicin-13-yl acetate; (1S,3S)-3-Acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-4-O-[(2R,4S,5S,6S)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2-yl]-α-L-lyxo-hexopyranoside 4-acetate 13-acetate
EINECS	Contact for details

Quality Control

Our production of this high-purity pharmaceutical intermediate adheres to stringent quality systems. Each batch is manufactured and controlled to meet exacting standards suitable for research and GMP-grade applications. Comprehensive testing includes identity confirmation (HPLC, MS, IR), purity assay (HPLC, typically ≥95% to ≥98%), and specific impurity profiling against known pharmacopeial standards such as the European Pharmacopoeia (EP) for related substances. A detailed Certificate of Analysis (COA) is provided with every shipment, ensuring full traceability and compliance with your research or quality protocols.

Storage

Preserve in a tightly closed container, protected from light. Due to its hygroscopic (moisture-sensitive) nature, the container should be stored in a cool, dry place, ideally at controlled room temperature (15-25°C). For long-term stability, consider storage under an inert atmosphere. Keep the container tightly sealed when not in use to prevent moisture absorption and decomposition.

Specification

Item	Specification
Appearance	Orange to red-orange powder
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Assay (HPLC)	≥ 95.0% - 98.0%
Related Substances (HPLC)	Total impurities ≤ 5.0% Any individual impurity ≤ 2.0%
Water Content (KF)	≤ 5.0%
Residue on Ignition	≤ 0.5%
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.